Giampaolo Bianchini

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Sara A. Hurvitz, Roberto Hegg, Wei‐Pang Chung et al. · The Lancet · 2022 · 580 citations · Full text

Breast Oncology, Medicine, Clinical Trials +8

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

Luca Gianni, Chiun‐Sheng Huang, Daniel Egle et al. · Annals of Oncology · 2022 · 365 citations · Full text

Advanced Breast Cancer, Breast Oncology, Oncology +7

Immunological differences between primary and metastatic breast cancer

Borbála Székely, Veerle Bossuyt, Xiaofeng Li et al. · Annals of Oncology · 2018 · 357 citations · Full text

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Fabrice André, Yeon Hee Park, Sung‐Bae Kim et al. · The Lancet · 2023 · 313 citations · Full text

Breast Oncology, Medicine, Clinical Trials +7

Spatial predictors of immunotherapy response in triple-negative breast cancer

Xiao Qian Wang, Esther Danenberg, Chiun‐Sheng Huang et al. · Nature · 2023 · 278 citations · Full text